HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]
, 2013 Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch +62 more
core +1 more source
Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]
, 2006 Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo +7 more
core +2 more sources
Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy. [PDF]
, 2016 Patient-derived xenograft (PDX) mouse models of cancer are emerging as an important component of personalized precision cancer therapy. However, most models currently offered to patients have their tumors subcutaneously-transplanted in immunodeficient ...
Bouvet, Michael +10 more
core +2 more sources
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12
Cell Death Discovery, 2021 Breast cancer is the most common cancer worldwide. JWA is a microtubule-associated protein that has been identified as a tumor suppressor, and its downregulation in tumors is an independent adverse prognostic factor.
Yan Liang +13 more
doaj +1 more source
Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab [PDF]
, 2012 Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to evaluate whether TZM cardiotoxicity involves inhibition
A. c. Wolff +12 more
core +1 more source
Advanced Functional Materials, EarlyView.Zr‐Fe MOF@Ribociclib@Herceptin (ZFRH) efficiently targets/kills Human Epidermal Growth Factor Receptor 2/Estrogen Receptor‐positive (HER2/ER+) breast cancer cells. It combats tumors by: 1) Elevating ROS, altering redox balance; 2) Inhibiting transcription; 3) Inducing pyroptosis.
Hongkun Miao +8 more
wiley +1 more source
Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]
, 2016 With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S. +6 more
core +2 more sources
Current perspective – Trastuzumab [PDF]
European Journal of Cancer, 2009 This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.
Peter Hall, David Cameron
openaire +3 more sources
Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology
Advanced Healthcare Materials, EarlyView.In vitro breast cancer models that closely mimic the complex biological and cellular interactions within the tumor microenvironment hold strong promise for enhancing our understanding of tumor progression, immune system behavior, and resistance to therapies, which are essential for developing personalized cancer treatments. Abstract Engineered in vitro
Wonwoo Jeong, Sang Jin Lee
wiley +1 more source